The biotech industry's prospects look promising due to the use of advanced technologies like AI and VR for research, the growing popularity of tailored treatments and biotech devices, a rise in chronic diseases, and increased R&D spending. Therefore, investors could consider buying biotech stocks Innoviva (INVA), Halozyme Therapeutics (HALO), Jazz Pharmaceuticals (JAZZ), and Entrada Therapeutics (TRDA), which are ready to surge in June. Read on...